Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
M	O
Service:	O
MEDICINE	O
Allergies:	O
shrimp	O
/	O
lisinopril	O
/	O
shellfish	O
derived	O
/	O
Iodinated	O
Contrast-	O
Oral	O
and	O
IV	O
Dye	O
/	O
fluorouracil	O
Attending:	O
___.	O
Chief	O
Complaint:	O
Right	O
upper	O
quadrant	O
abdominal	O
pain	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
Cardiac	O
catheterization	O
___	O
with	O
no	O
interventions	O
History	O
of	O
Present	O
Illness:	O
___	O
PMH	O
prostate	O
cancer	O
(s/p	O
brachytherapy	O
___,	O
metastatic	O
HER-2	O
positive	O
esophageal	O
adenocarcinoma	O
(progressed	O
on	O
multiple	O
regimens,	O
s/p	O
cycle	O
2	O
pembrolizumab),	O
HLD,	O
T2DM,	O
who	O
presented	O
to	O
ED	O
___	O
with	O
RUQ	O
pain.	O
As	O
per	O
review	O
of	O
most	O
recent	O
outpatient	O
oncology	O
note,	O
Dr	O
___	O
planned	O
to	O
give	O
3	O
cycles	O
of	O
pembrolizumab	O
prior	O
to	O
re-staging	O
disease.	O
He	O
is	O
s/p	O
cycle	O
2.	O
On	O
this	O
admission,	O
he	O
presented	O
with	O
RUQ	O
pain.	O
He	O
explained	O
that	O
he	O
has	O
been	O
fatigued	O
over	O
the	O
past	O
several	O
weeks,	O
but	O
then	O
yesterday	O
out	O
of	O
the	O
blue,	O
had	O
sharp	O
RUQ	O
pain,	O
Right	O
shoulder	O
pain,	O
and	O
pain	O
with	O
deep	O
inspiration.	O
He	O
noted	O
that	O
he	O
was	O
without	O
SOB,	O
palpitations,	O
chest	O
discomfort.	O
Noted	O
that	O
symptoms	O
are	O
worse	O
when	O
laying	O
on	O
his	O
right	O
side.	O
Denied	O
periods	O
of	O
immobility	O
or	O
leg	O
swelling.	O
Noted	O
that	O
he	O
never	O
had	O
such	O
symptoms	O
before.	O
Noted	O
that	O
he	O
only	O
had	O
intermittent	O
abdominal	O
discomfort	O
for	O
which	O
he	O
took	O
MS	O
contin	O
intermittently,	O
and	O
rarely	O
oxycodone	O
(as	O
he	O
fears	O
he	O
will	O
be	O
addicted).	O
Denied	O
fever,	O
chills,	O
headache,	O
SOB,	O
dysuria,	O
rash,	O
sick	O
contacts.	O
In	O
the	O
ED,	O
initial	O
vitals:	O
37.5	O
116	O
126/82	O
___	O
FSG	O
153.	O
Temperature	O
in	O
ED	O
maxed	O
at	O
100.6.	O
WBC	O
12.7,	O
Hgb	O
10.6,	O
plt	O
347,	O
CEA	O
716.6,	O
ALT	O
60	O
AST	O
49,	O
AP	O
184,	O
Phos	O
2.3,	O
Ca	O
___	O
CHEM	O
w/	O
Cr	O
1.1,	O
lactate	O
1.1,	O
UA	O
1WBC,	O
few	O
bacteria,	O
+	O
Glucose	O
+	O
protein.	O
Blood	O
+	O
urine	O
cultures	O
sent.	O
RUQUS:	O
1.	O
No	O
biliary	O
ductal	O
dilatation.	O
No	O
findings	O
of	O
acute	O
cholecystitis.	O
2.	O
Known	O
hepatic	O
metastases.	O
3.	O
Predominantly	O
hepatopetal,	O
though	O
bidirectional	O
portal	O
vein	O
flow,	O
new	O
from	O
prior.	O
Patent	O
main	O
portal	O
vein.	O
CT	O
A/P:	O
-No	O
evidence	O
of	O
intra-abdominal	O
or	O
pelvic	O
infection	O
within	O
the	O
limitations	O
of	O
an	O
unenhanced	O
scan.	O
-Interval	O
increase	O
in	O
size	O
and	O
number	O
of	O
hepatic	O
hypodensities,	O
along	O
with	O
increased	O
prominence	O
of	O
porta	O
hepatis	O
lymph	O
nodes,	O
is	O
worrisome	O
for	O
disease	O
progression.	O
CXR:	O
No	O
infection	O
on	O
my	O
read,	O
but	O
final	O
review	O
by	O
radiology	O
pending	O
Patient	O
was	O
given	O
vancomycin,	O
zosyn,	O
NS,	O
MS	O
contin,	O
___	O
and	O
admitted	O
for	O
further	O
care.	O
REVIEW	O
OF	O
SYSTEMS:	O
A	O
complete	O
10-point	O
review	O
of	O
systems	O
was	O
performed	O
and	O
was	O
negative	O
unless	O
otherwise	O
noted	O
in	O
the	O
HPI.	O
Past	O
Medical	O
History:	O
PAST	O
ONCOLOGIC	O
HISTORY:	O
As	O
per	O
last	O
clinic	O
note	O
by	O
Dr	O
___:	O
"Prostate	O
cancer:	O
-	O
PSA	O
slowly	O
rising	O
from	O
___	O
-	O
___:	O
Bx	O
showed	O
___	O
3+4	O
disease	O
involving	O
60%	O
of	O
a	O
fragmented	O
core	O
from	O
the	O
right	O
lateral	O
apex	O
with	O
pattern	O
4	O
seen	O
as	O
a	O
minute	O
component	O
of	O
a	O
few	O
poorly	O
formed	O
glands	O
in	O
one	O
of	O
the	O
core	O
fragments.	O
An	O
additional	O
three	O
cores	O
had	O
___	O
3+3	O
disease	O
involving	O
less	O
than	O
5%	O
or	O
5%	O
of	O
each	O
core	O
from	O
the	O
right	O
mid	O
lateral	O
prostate,	O
right	O
mid	O
medial	O
prostate	O
and	O
right	O
lateral	O
base.	O
-	O
___:	O
brachytherapy	O
Esophageal	O
cancer:	O
-	O
Long	O
history	O
of	O
anemia	O
and	O
bright	B-Lower_gastrointestinal_haemorrhage
red	B-Lower_gastrointestinal_haemorrhage
blood	B-Lower_gastrointestinal_haemorrhage
per	B-Lower_gastrointestinal_haemorrhage
rectum	B-Lower_gastrointestinal_haemorrhage
attributed	O
to	O
hemorrhoids.	B-Lower_gastrointestinal_haemorrhage
-	O
___:	O
EGD	O
showed	O
an	O
esophageal	O
mass,	O
Bx	O
moderately	O
differentiated	O
adenocarcinoma.	O
Colonoscopy	O
was	O
normal.	O
-	O
___:	O
EUS	O
with	O
Bx	O
showed	O
adenocarcinoma	O
of	O
the	O
lower	O
esophagus,	O
T3N1	O
by	O
EUS	O
staging.	O
-	O
___:	O
CT	O
Torso	O
without	O
contrast	O
showed	O
no	O
evidence	O
of	O
distant	O
disease,	O
although	O
limited	O
by	O
lack	O
of	O
contrast	O
agent.	O
-	O
___:	O
PET	O
showed	O
2	O
possible	O
sites	O
of	O
liver	O
metastases,	O
a	O
large	O
focus	O
in	O
the	O
caudate	O
lobe	O
with	O
SUVmax	O
14.7	O
and	O
a	O
smaller	O
area	O
in	O
the	O
dome	O
with	O
SUVmax	O
3.2.	O
-	O
___:	O
port	O
placement	O
-	O
___:	O
liver	O
Bx,	O
ultrasound	O
showed	O
multiple	O
lesions,	O
pathology	O
shows	O
metastatic	O
adeno	O
-	O
___:	O
increased	O
abdominal	O
pain,	O
referred	O
to	O
ED.	O
CT	O
A/P	O
showed	O
multiple	O
liver	O
lesions,	O
as	O
on	O
ultrasound.	O
-	O
___:	O
C1D1	O
FOLFOX/Herceptin	O
-	O
___:	O
admitted	O
for	O
chest	O
pain,	O
hematemesis.	B-Upper_gastrointestinal_haemorrhage
Concern	O
for	O
___	O
chest	O
pain	O
vs.	O
bleeding	B-Upper_gastrointestinal_haemorrhage
esophageal	B-Upper_gastrointestinal_haemorrhage
mass.	O
EGD	B-Upper_gastrointestinal_haemorrhage
showed	O
large	O
fungating	O
mass	O
but	O
no	O
active	O
bleeding.	B-Upper_gastrointestinal_haemorrhage
-	O
___:	O
___	O
cGy	O
in	O
3	O
fx	O
delivered	O
to	O
lower	O
esophagus/GE	O
junction	O
mass	O
-	O
___:	O
C1D15	O
Herceptin	O
only	O
(low	O
counts)	O
-	O
___:	O
C1D15	O
FOLFOX	O
HELD	O
due	O
to	O
___	O
1420	O
-	O
___:	O
C1D15	O
FOLFOX	O
given,	O
admitted	O
for	O
chest	O
pain	O
-	O
___:	O
C1D1	O
___	O
-	O
___:	O
C2D1	O
___	O
-	O
___:	O
C3D1	O
___	O
-	O
___:	O
C4D1	O
___	O
HELD	O
for	O
abdominal	O
pain,	O
likely	O
progression	O
-	O
___:	O
celiac	O
plexus	O
neurolysis	O
-	O
___:	O
C1D1	O
irinotecan/Herceptin	O
-	O
___:	O
C2D1	O
irinotecan/Herceptin	O
-	O
___:	O
C3D1	O
irinotecan/Herceptin	O
-	O
___:	O
C4D1	O
irinotecan/Herceptin;	O
PET	O
overall	O
stable	O
but	O
with	O
some	O
evidence	O
of	O
progression	O
in	O
some	O
lesions,	O
CEA	O
rising	O
-	O
___:	O
C1	O
pembrolizumab	O
-	O
___:	O
C2	O
pembrolizumab"	O
PAST	O
MEDICAL	O
HISTORY:	O
-T2DM	O
-HLD	O
-Hyperparathyroidism	O
-Meniscal	O
tear	O
s/p	O
knee	O
arthroscopy	O
(3	O
R	O
knee,	O
2	O
L	O
knee)	O
-Osteoarthritis	O
-Chest	O
pain	O
___	O
Social	O
History:	O
___	O
Family	O
History:	O
Mother:	O
living	O
age	O
___	O
Father:	O
died	O
age	O
___,	O
no	O
medical	O
issues	O
Cancers	O
in	O
the	O
family:	O
none	O
Physical	O
Exam:	O
ADMISSION	O
EXAM:	O
================	O
Vitals:	O
___	O
___	O
Temp:	O
98.2	O
PO	O
BP:	O
108/74	O
HR:	O
78	O
RR:	O
18	O
O2	O
sat:	O
98%	O
O2	O
delivery:	O
Ra	O
GENERAL:	O
Sitting	O
upright	O
in	O
bed,	O
appears	O
calm,	O
comfortable	O
until	O
takes	O
a	O
deep	O
breath	O
then	O
winces	O
EYES:	O
PERRLA,	O
anicteric	O
HEENT:	O
OP	O
clear,	O
MMM	O
NECK:	O
supple	O
LUNGS:	O
CTA	O
b/l,	O
no	O
wheezes/rales/rhonchi,	O
normal	O
RR,	O
winces	O
when	O
taking	O
deep	O
breaths	O
CV:	O
RRR	O
no	O
murmurs,	O
rubs,	O
or	O
gallops,	O
normal	O
distal	O
perfusion,	O
no	O
edema	O
ABD:	O
soft,	O
NT,	O
ND,	O
normoactive	O
BS,	O
no	O
rebound	O
or	O
guarding	O
GENITOURINARY:	O
no	O
foley	O
EXT:	O
warm,	O
no	O
deformity,	O
normal	O
muscle	O
bulk	O
SKIN:	O
warm,	O
dry,	O
no	O
rash	O
NEURO:	O
AOX3,	B-Delirium
fluent	O
speech	O
ACCESS:	O
R	O
chest	O
PORT	O
dressing	O
c/d/i	O
.	O
.	O
DISCHARGE	O
EXAM:	O
===============	O
Vitals:	O
24	O
HR	O
Data	O
(last	O
updated	O
___	O
@	O
829)	O
Temp:	O
99.1	O
(Tm	O
99.7),	O
BP:	O
109/70	O
(101-123/65-81),	O
HR:	O
95	O
(93-105),	O
RR:	O
16	O
(___),	O
O2	O
sat:	O
96%	O
(93-96),	O
O2	O
delivery:	O
RA,	O
Wt:	O
191.2	O
lb/86.73	O
kg	O
GENERAL:	O
Sitting	O
upright	O
in	O
bed,	O
appears	O
calm,	O
comfortable	O
until	O
takes	O
a	O
deep	O
breath	O
then	O
winces	O
EYES:	O
PERRLA,	O
anicteric	O
HEENT:	O
OP	O
clear,	O
MMM	O
NECK:	O
supple	O
LUNGS:	O
CTA	O
b/l,	O
no	O
wheezes/rales/rhonchi,	O
normal	O
RR,	O
winces	O
when	O
taking	O
deep	O
breaths	O
CV:	O
RRR	O
no	O
murmurs,	O
rubs,	O
or	O
gallops,	O
normal	O
distal	O
perfusion,	O
no	O
edema	O
ABD:	O
soft,	O
NT,	O
ND,	O
normoactive	O
BS,	O
no	O
rebound	O
or	O
guarding	O
GENITOURINARY:	O
no	O
foley	O
EXT:	O
warm,	O
no	O
deformity,	O
normal	O
muscle	O
bulk	O
SKIN:	O
warm,	O
dry,	O
no	O
rash	O
NEURO:	O
AOX3,	B-Delirium
fluent	O
speech	O
ACCESS:	O
R	O
chest	O
PORT	O
dressing	O
c/d/i	O
Pertinent	O
Results:	O
ADMISSION	O
LABS:	O
===============	O
___	O
12:45PM	O
BLOOD	O
WBC-12.7*	O
RBC-4.50*	O
Hgb-10.6*	O
Hct-34.0*	O
MCV-76*	O
MCH-23.6*	O
MCHC-31.2*	O
RDW-15.5	O
RDWSD-42.3	O
Plt	O
___	O
___	O
10:30PM	O
BLOOD	O
Neuts-71.6*	O
Lymphs-10.2*	O
Monos-14.5*	O
Eos-2.3	O
Baso-0.9	O
Im	O
___	O
AbsNeut-9.22*	O
AbsLymp-1.31	O
AbsMono-1.86*	O
AbsEos-0.29	O
AbsBaso-0.11*	O
___	O
12:45PM	O
BLOOD	O
UreaN-13	O
Creat-1.1	O
Na-135	O
K-5.2	O
Cl-97	O
HCO3-25	O
AnGap-13	O
___	O
12:45PM	O
BLOOD	O
ALT-60*	O
AST-49*	O
AlkPhos-184*	O
TotBili-0.3	O
___	O
12:45PM	O
BLOOD	O
Albumin-3.8	O
Calcium-11.2*	O
Phos-2.3*	O
Mg-2.3	O
___	O
12:45PM	O
BLOOD	O
CEA-716.6*	O
___	O
12:45PM	O
BLOOD	O
Free	O
T4-1.2	O
___	O
12:45PM	O
BLOOD	O
TSH-2.4	O
___	O
10:37PM	O
BLOOD	O
Lactate-1.1	O
.	O
.	O
MICRO:	O
======	O
-___	O
BCx:	O
NG	O
-___	O
UCx:	O
no	O
significant	O
growth	O
(final)	O
-___	O
BCx:	O
NG	O
-___	O
BCx:	O
.	O
IMAGING:	O
=========	O
___	O
RUQUS:	O
"1.	O
No	O
biliary	O
ductal	O
dilatation.	O
No	O
findings	O
of	O
acute	O
cholecystitis.	O
2.	O
Multiple	O
hepatic	O
metastases,	O
as	O
previously	O
demonstrated	O
on	O
prior	O
cross-sectional	O
studies.	O
3.	O
To	O
and	O
fro	O
flow	O
within	O
the	O
main	O
portal	O
vein,	O
new	O
from	O
prior,	O
is	O
suggestive	O
of	O
early	O
portal	O
hypertension."	O
___	O
CT	O
A/P:	O
-"No	O
evidence	O
of	O
intra-abdominal	O
or	O
pelvic	O
infection	O
within	O
the	O
limitations	O
of	O
an	O
unenhanced	O
scan."	O
-"Interval	O
increase	O
in	O
size	O
and	O
number	O
of	O
hepatic	O
hypodensities,	O
along	O
with	O
increased	O
prominence	O
of	O
porta	O
hepatis	O
lymph	O
nodes,	O
is	O
worrisome	O
for	O
disease	O
progression."	O
___	O
CXR:	O
-	O
"No	O
acute	O
cardiopulmonary	O
process."	O
.	O
.	O
DISCHARGE	O
LABS:	O
===============	O
___	O
06:55AM	O
BLOOD	O
WBC-11.5*	O
RBC-3.87*	O
Hgb-8.9*	O
Hct-28.3*	O
MCV-73*	O
MCH-23.0*	O
MCHC-31.4*	O
RDW-15.6*	O
RDWSD-40.8	O
Plt	O
___	O
___	O
05:17AM	O
BLOOD	O
Glucose-154*	O
UreaN-12	O
Creat-0.9	O
Na-135	O
K-3.8	O
Cl-99	O
HCO3-23	O
AnGap-13	O
___	O
06:09AM	O
BLOOD	O
ALT-30	O
AST-29	O
AlkPhos-149*	O
TotBili-0.6	O
___	O
05:17AM	O
BLOOD	O
Calcium-9.8	O
Phos-2.3*	O
Mg-1.9	O
CARDIAC	O
CATH	O
___:	O
FINDINGS:	O
Normal	O
left	O
and	O
right	O
heart	O
filling	O
pressures.	O
RECOMMENDATIONS:	O
Maximize	O
medical	O
therapy.	O
Brief	O
Hospital	O
Course:	O
PATIENT	O
SUMMARY	O
================	O
___	O
PMH	O
prostate	O
cancer	O
(s/p	O
brachytherapy	O
___,	O
metastatic	O
HER-2	O
positive	O
esophageal	O
adenocarcinoma	O
(progressed	O
on	O
multiple	O
regimens,	O
s/p	O
cycle	O
2	O
pembrolizumab),	O
HLD,	O
T2DM,	O
who	O
presented	O
to	O
ED	O
with	O
sharp	O
RUQ	O
pain,	O
right	O
shoulder	O
pain,	O
and	O
pain	O
with	O
deep	O
inspiration	O
x	O
1	O
day	O
on	O
___.	O
Work	O
up	O
for	O
infection	O
was	O
negative	O
and	O
pain	O
deemed	O
to	O
be	O
pain	O
from	O
capsular	O
distension	O
from	O
his	O
growing	O
liver	O
metastasis	O
shown	O
on	O
CT	O
done	O
___.	O
Due	O
to	O
limited	O
options	O
and	O
with	O
input	O
of	O
cardio-oncology	O
consultation,	O
decision	O
was	O
made	O
to	O
retry	O
FOLFOX	O
regimen	O
despite	O
prior	O
episodes	O
of	O
documented	O
coronary	O
vasospasm.	O
Calcium	O
channel	O
blocker	O
and	O
long	O
acting	O
nitrate	O
was	O
initiated	O
prior	O
to	O
treating	O
with	O
FOLFOX	O
in	O
order	O
to	O
attempt	O
to	O
prevent	O
recurrent	O
vasospasm.	O
FOLFOX	O
initiated	O
___,	O
however,	O
again	O
complicated	O
by	O
chest	O
pain	O
with	O
ST	O
elevations	O
with	O
quick	O
resolution	O
with	O
SL	O
NTG	O
c/w	O
coronary	O
vasospasm.	O
Episode	O
of	O
recurrent	O
CP	O
that	O
night	O
despite	O
stopping	O
___	O
infusion	O
prompting	O
FICU	O
transfer	O
for	O
possible	O
nitro	O
gtt.	O
TTE	O
done	O
in	O
FICU	O
remarkable	O
for	O
new	O
decreased	O
EF	O
of	O
30%	O
with	O
global	O
hypokinesis.	O
No	O
troponin	O
or	O
CKmb	O
elevation	O
was	O
noted,	O
which	O
supported	O
direct	O
cardiotoxicity	O
of	O
___	O
rather	O
than	O
an	O
ischemic	O
event	O
related	O
to	O
coronary	O
vasospasm.	O
Due	O
to	O
the	O
new	O
cardiomyopathy,	O
cardiology	O
recommended	O
a	O
cardiac	O
catheterization	O
to	O
rule	O
out	O
ischemic	O
cardiomyopathy	O
and	O
significant	O
atherosclerotic	O
lesion	O
precipitating	O
vasospasm.	O
Cath	O
done	O
on	O
___	O
was	O
notable	O
for	O
absence	O
of	O
obstructive	O
CAD.	O
Based	O
on	O
direct	O
cardiac	O
toxicity,	O
patient	O
will	O
not	O
be	O
trialed	O
on	O
___	O
again.	O
His	O
primary	O
oncologist,	O
Dr.	O
___	O
met	O
with	O
the	O
patient	O
and	O
discussed	O
the	O
likely	O
limited	O
utility	O
of	O
further	O
aggressive	O
chemotherapy,	O
but	O
left	O
the	O
options	O
open	O
for	O
trying	O
alternative	O
regimens	O
going	O
forward.	O
He	O
was	O
discharged	O
with	O
oncology	O
follow	O
up	O
___.	O
ACUTE	O
ISSUES	O
============	O
#	O
RUQ	O
abdominal	O
Pain,	O
Indigestion:	O
#	O
___	O
induced	O
coronary	O
vasospasm	O
and	O
cardiotoxicity	O
#Metastatic	O
Esophageal	O
Adenocarcinoma:	O
See	O
extensive	O
oncologic	O
history	O
in	O
admission	O
H&P.	O
Overall,	O
patient	O
has	O
progressed	O
through	O
multiple	O
treatment	O
regimens.	O
CEA	O
did	O
have	O
some	O
downtrend	O
in	O
limited	O
exposure	O
to	O
FOLFOX,	O
but	O
had	O
two	O
incomplete	O
cycles	O
___	O
documented	O
coronary	O
vasospasm	O
from	O
___.	O
CT	O
scan	O
___	O
showed	O
continued	O
progression	O
of	O
disease	O
despite	O
pembro	O
treatment.	O
Decision	O
was	O
made	O
to	O
again	O
try	O
FOLFOX	O
with	O
medical	O
therapy	O
designed	O
to	O
prevent	O
vasospasm	O
(CCB	O
and	O
nitrates).	O
This	O
unfortunately	O
failed	O
as	O
patient	O
had	O
diffuse	O
(primarily	O
anterior)	O
ST	O
elevations	O
and	O
chest	O
pain	O
26	O
hr's	O
after	O
initiation	O
of	O
___	O
infusion.	O
Required	O
ICU	O
transfer	O
for	O
monitoring.	O
No	O
troponin	O
or	O
CKmb,	O
but	O
TTE	O
with	O
new	O
decrease	O
in	O
EF	O
to	O
30%	O
best	O
explained	O
by	O
direct	O
cardiotoxic	O
effect	O
of	O
___	O
vs	O
Stunning	O
from	O
___	O
and/or	O
large	O
CCB	O
dose.	O
Symptomatic	O
improvement	O
was	O
achieved	O
with	O
new	O
medications	O
outlined	O
below	O
in	O
the	O
transitional	O
issues.	O
Chemotherapy	O
options	O
going	O
forward	O
are	O
quite	O
limited	O
and	O
this	O
was	O
discussed	O
with	O
the	O
patient	O
in	O
detail,	O
both	O
from	O
the	O
OMED	O
team	O
and	O
from	O
his	O
primary	O
oncologist	O
ML	O
___.	O
#	O
New	O
HFrEF	O
(EF	O
30%):	O
New	O
___	O
TTE	O
with	O
EF	O
of	O
30%	O
and	O
global	O
hypokinesis	O
(had	O
normal	O
EF	O
on	O
___	O
TTE).	O
Had	O
event	O
of	O
coronary	O
vasospasm	O
and	O
___	O
infusion	O
in	O
the	O
interval	O
between	O
those	O
TTE's,	O
but	O
no	O
troponin	O
or	O
CKmb	O
elevation	O
to	O
suggest	O
infarction.	O
Thought	O
to	O
be	O
from	O
stunning	O
from	O
___	O
vs.	O
direct	O
cardiotoxic	O
effect	O
of	O
___.	O
Patient	O
asymptomatic	O
and	O
euvolemic.	O
Cardiac	O
cath	O
___	O
without	O
obstructive	O
CAD.	O
Initiated	O
on	O
goal	O
directed	O
therapy,	O
discharged	O
on	O
home	O
losartan	O
25	O
and	O
new	O
metoprolol	O
XL	O
50	O
mg	O
daily.	O
Aspirin	O
and	O
atorvastatin	O
were	O
continued	O
but	O
their	O
utility	O
should	O
be	O
evaluated	O
going	O
forward	O
given	O
poor	O
prognosis	O
from	O
cancer	O
and	O
absence	O
of	O
obstructing	O
CAD.	O
#Fever	O
#Leukocytosis	O
The	O
patient	O
was	O
found	O
to	O
be	O
febrile	O
on	O
presentation	O
to	O
ED	O
and	O
received	O
1	O
dose	O
vanc/zosyn.	O
Has	O
been	O
intermittently	O
febrile	O
overnight	O
but	O
no	O
further	O
antibiotics	O
given	O
as	O
thought	O
to	O
be	O
malignancy	O
driven.	O
Infectious	O
workup	O
was	O
negative.	O
Patient	O
also	O
with	O
mild	O
leukocytosis	O
but	O
appears	O
to	O
be	O
stable.	O
No	O
focal	O
symptoms	O
to	O
suggest	O
infection.	O
VQ	O
scan	O
and	O
duplex	O
negative	O
making	O
DVT	O
or	O
PE	O
less	O
likely	O
as	O
a	O
cause	O
of	O
fever.	O
#Anemia	O
Patient	O
with	O
chronic	O
anemia	O
with	O
a	O
hemoglobin	O
around	O
10	O
in	O
the	O
setting	O
of	O
active	O
malignancy.	O
Patient	O
also	O
has	O
a	O
history	O
of	O
hemorrhoids	O
and	O
had	O
an	O
episode	O
of	O
bright	B-Lower_gastrointestinal_haemorrhage
red	B-Lower_gastrointestinal_haemorrhage
blood	B-Lower_gastrointestinal_haemorrhage
per	B-Lower_gastrointestinal_haemorrhage
rectum.	B-Lower_gastrointestinal_haemorrhage
On	O
admission	O
the	O
patient's	O
hemoglobin	O
was	O
around	O
8	O
and	O
has	O
been	O
there	O
since	O
about	O
___.	O
Iron	O
studies	O
showed	O
a	O
low	O
iron	O
low	O
ferritin	O
and	O
elevated	O
TIBC.	O
Given	O
his	O
low	O
iron	O
the	O
patient	O
was	O
not	O
immediately	O
transfused	O
given	O
active	O
chemotherapy	O
infusion.	O
#Mild	O
Hypercalcemia/Hyperparathyroidism	O
Patient	O
with	O
corrected	O
calcium	O
of	O
11	O
on	O
admission.	O
This	O
was	O
thought	O
to	O
be	O
due	O
to	O
primary	O
hyperparathyroidism	O
and	O
PTH	O
level	O
was	O
elevated	O
which	O
is	O
consistent	O
with	O
that	O
diagnosis.	O
The	O
patient's	O
calcium	O
was	O
monitored	O
daily	O
during	O
his	O
admission.	O
CHRONIC	O
ISSUES	O
==============	O
#Constipation	I-Constipation
Thought	O
to	O
be	O
opioid	O
induced	O
constipation	B-Constipation
that	O
was	O
treated	O
with	O
MiraLAX	O
and	O
senna	O
and	O
lactulose.	O
#Hypertension	O
-	O
Home	O
losartan	O
25mg	O
#Diabetes	O
Mellitus,	O
Type	O
2	O
Appears	O
to	O
be	O
well	O
controlled	O
with	O
most	O
readings	O
<	O
200.	O
restarted	O
home	O
metformin	O
on	O
discharge	O
Transitional	O
Issues	O
====================	O
NEW	O
MEDICATIONS	O
-	O
Cardiac	O
Meds:	O
Metoprolol	O
XL	O
50	O
mg	O
daily,	O
aspirin,	O
atorvastatin.	O
-	O
GI	O
Meds:	O
Omeprazole	O
20	O
mg	O
BID,	O
Sucralfate	O
QID,	O
Polyethylene	O
glycol	O
BID:PRN,	O
Senna	O
BID,	O
Simethacone	O
BID	O
[	O
]	O
Increase	O
metoprolol	O
and	O
losartan	O
doses	O
as	O
tolerated	O
to	O
encourage	O
cardiac	O
recovery.	O
[	O
]	O
Patient	O
has	O
direct	O
cardiotoxicity	O
and	O
coronary	O
vasospasm	O
from	O
___,	O
do	O
not	O
give	O
this	O
medication.	O
[	O
]	O
Patient	O
has	O
limited	O
chemotherapy	O
options	O
going	O
forward	O
and	O
has	O
relatively	O
poor	O
prognosis	O
despite	O
good	O
functional	O
status.	O
[	O
]	O
Patient	O
had	O
significant	O
symptomatic	O
improvement	O
with	O
the	O
addition	O
of	O
the	O
GI	O
medications	O
above	O
[	O
]	O
Patient	O
has	O
had	O
intermittent	O
fevers	O
without	O
infectious	O
source,	O
suspect	O
tumor	O
fevers.	O
[	O
]	O
Patient	O
has	O
remained	O
full	O
code	O
despite	O
likely	O
limited	O
life	O
span	O
going	O
forward,	O
please	O
address	O
in	O
the	O
outpatient	O
setting.	O
[	O
]	O
If	O
limited	O
by	O
decreased	O
EF	O
in	O
terms	O
of	O
chemo	O
regimen,	O
recommend	O
repeating	O
TTE	O
in	O
___	O
weeks	O
as	O
suspect	O
likely	O
to	O
have	O
recovery	O
of	O
EF.	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
Tamsulosin	O
0.4	O
mg	O
PO	O
QHS	O
2.	O
Ferrous	O
GLUCONATE	O
324	O
mg	O
PO	O
DAILY	O
3.	O
Losartan	O
Potassium	O
25	O
mg	O
PO	O
DAILY	O
4.	O
MetFORMIN	O
(Glucophage)	O
500	O
mg	O
PO	O
BID	O
5.	O
Morphine	O
SR	O
(MS	O
___	O
15	O
mg	O
PO	O
Q12H	O
6.	O
OxyCODONE	O
(Immediate	O
Release)	O
10	O
mg	O
PO	O
Q4H:PRN	O
Pain	O
-	O
Moderate	O
Discharge	O
Medications:	O
1.	O
Acetaminophen	O
650	O
mg	O
PO	O
Q6H:PRN	O
Pain	O
-	O
Mild/Fever	O
2.	O
Aspirin	O
81	O
mg	O
PO	O
DAILY	O
RX	O
*aspirin	O
81	O
mg	O
1	O
tablet(s)	O
by	O
mouth	O
daily	O
Disp	O
#*30	O
Tablet	O
Refills:*3	O
3.	O
Atorvastatin	O
40	O
mg	O
PO	O
QPM	O
RX	O
*atorvastatin	O
40	O
mg	O
1	O
tablet(s)	O
by	O
mouth	O
daily	O
Disp	O
#*30	O
Tablet	O
Refills:*3	O
4.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
BID	O
RX	O
*docusate	O
sodium	O
100	O
mg	O
1	O
capsule(s)	O
by	O
mouth	O
twice	O
a	O
day	O
Disp	O
#*60	O
Capsule	O
Refills:*1	O
5.	O
Metoprolol	O
Succinate	O
XL	O
50	O
mg	O
PO	O
DAILY	O
RX	O
*metoprolol	O
succinate	O
50	O
mg	O
1	O
tablet(s)	O
by	O
mouth	O
Daily	O
Disp	O
#*30	O
Tablet	O
Refills:*2	O
6.	O
Omeprazole	O
20	O
mg	O
PO	O
BID	O
RX	O
*omeprazole	O
20	O
mg	O
1	O
capsule(s)	O
by	O
mouth	O
twice	O
a	O
day	O
Disp	O
#*60	O
Capsule	O
Refills:*2	O
7.	O
Polyethylene	O
Glycol	O
17	O
g	O
PO	O
BID	O
Ok	O
to	O
hold	O
for	O
loose	O
stools	O
RX	O
*polyethylene	O
glycol	O
3350	O
17	O
gram	O
1	O
powder(s)	O
by	O
mouth	O
BID:PRN	O
Disp	O
#*30	O
Packet	O
Refills:*2	O
8.	O
Senna	O
8.6	O
mg	O
PO	O
BID	O
Ok	O
to	O
hold	O
for	O
loose	O
stools	O
RX	O
*sennosides	O
[senna]	O
8.6	O
mg	O
1	O
by	O
mouth	O
twice	O
a	O
day	O
Disp	O
#*60	O
Tablet	O
Refills:*1	O
9.	O
Simethicone	O
40-80	O
mg	O
PO	O
QID:PRN	O
belching	O
RX	O
*simethicone	O
80	O
mg	O
1	O
by	O
mouth	O
QID:PRN	O
Disp	O
#*120	O
Tablet	O
Refills:*1	O
10.	O
Sucralfate	O
1	O
gm	O
PO	O
QID	O
RX	O
*sucralfate	O
[Carafate]	O
1	O
gram	O
1	O
tablet(s)	O
by	O
mouth	O
four	O
times	O
a	O
day	O
Disp	O
#*120	O
Tablet	O
Refills:*2	O
11.	O
Ferrous	O
GLUCONATE	O
324	O
mg	O
PO	O
DAILY	O
12.	O
Losartan	O
Potassium	O
25	O
mg	O
PO	O
DAILY	O
13.	O
MetFORMIN	O
(Glucophage)	O
500	O
mg	O
PO	O
BID	O
14.	O
Morphine	O
SR	O
(MS	O
___	O
15	O
mg	O
PO	O
Q12H	O
15.	O
OxyCODONE	O
(Immediate	O
Release)	O
10	O
mg	O
PO	O
Q4H:PRN	O
Pain	O
-	O
Moderate	O
Discharge	O
Disposition:	O
Home	O
Discharge	O
Diagnosis:	O
Primary	O
Diagnosis	O
==================	O
Intermittent	O
acute	O
right	O
upper	O
quadrant	O
abdominal	O
pain	O
Hepatic	O
distention	O
syndrome	O
Metastatic	O
esophageal	O
cancer	O
Secondary	O
Diagnosis	O
===================	O
Constipation	B-Constipation
Anemia	O
Hypertension	O
Type	O
2	O
diabetes	O
Discharge	O
Condition:	O
Mental	O
Status:	O
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Independently_mobile
-	B-Independently_mobile
Independent.	B-Independently_mobile
Discharge	O
Instructions:	O
Dear	O
Mr.	O
___,	O
It	O
has	O
been	O
a	O
privilege	O
to	O
assist	O
in	O
your	O
care.	O
You	O
were	O
admitted	O
with	O
right	O
upper	O
abdominal	O
pain.	O
We	O
did	O
very	O
extensive	O
imaging	O
and	O
other	O
testing.	O
The	O
pain	O
is	O
likely	O
from	O
stretching	O
of	O
the	O
liver	O
capsule	O
due	O
to	O
cancer.	O
We	O
adjusted	O
your	O
medications	O
for	O
pain	O
and	O
for	O
preventing	O
constipation.	B-Constipation
We	O
talked	O
to	O
specialty	O
teams	O
including	O
heart	O
doctors	O
and	O
your	O
___	O
doctor.	O
You	O
were	O
started	O
on	O
chemotherapy	O
and	O
monitored	O
closely	O
for	O
any	O
reactions.	O
Unfortunately	O
you	O
suffered	O
a	O
cardiac	O
event	O
likely	O
related	O
to	O
the	O
FOLFOX	O
chemotherapy.	O
The	O
chemotherapy	O
was	O
stopped	O
and	O
cardiology	O
saw	O
you.	O
Cardiology	O
performed	O
a	O
coronary	O
angiography	O
which	O
showed	O
that	O
you	O
did	O
not	O
have	O
any	O
blockages	O
in	O
the	O
arteries	O
of	O
your	O
heart.	O
Dr.	O
___	O
that,	O
unfortunately,	O
your	O
cancer	O
has	O
not	O
been	O
particularly	O
sensitive.	O
For	O
that	O
reason,	O
she	O
is	O
not	O
planning	O
on	O
giving	O
you	O
further	O
chemo	O
at	O
this	O
time.	O
Instead,	O
we	O
intent	O
to	O
focus	O
on	O
maximizing	O
your	O
quality	O
of	O
life	O
and	O
decreasing	O
your	O
symptoms.	O
You	O
will	O
meet	O
with	O
your	O
cancer	O
doctor,	O
___,	O
in	O
clinic	O
to	O
discuss	O
your	O
next	O
options	O
for	O
chemotherapy.	O
Sincerely,	O
Your	O
___	O
Team	O
Followup	O
Instructions:	O
___	O

